Ciencias de la vida y de la materia Terapias oncológicas avanzadas

Biomateriales y biotecnología: desde el descubrimiento de los inhibidores angiogénicos hasta el desarrollo de los sistemas de liberación controlada de fármacos y la ingeniería de tejido

15/10/2014

Descripción
Robert S. Langer is the David H. Koch Institute Professor (there are 11 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member). Dr. Langer has written over 1,250 articles. He also has nearly 1,050 patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 250 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history. He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 -- 2002 and as its Chairman from 1999-2002.
"La Fundación Ramón Areces no se hace responsable de las opiniones, comentarios o manifestaciones realizados por las personas que participan en sus actividades."

Descripción

Robert S. Langer is the David H. Koch Institute Professor (there are 11 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member). Dr. Langer has written over 1,250 articles. He also has nearly 1,050 patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 250 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history. He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 -- 2002 and as its Chairman from 1999-2002.

"La Fundación Ramón Areces no se hace responsable de las opiniones, comentarios o manifestaciones realizados por las personas que participan en sus actividades."

Vídeos
Ciencias de la vida y de la materia Terapias oncológicas avanzadas

Integración de la medicina personalizada frente al cáncer en el descubrimiento y desarrollo de fármacos

15/10/2014

Tratamiento personalizado del cáncer: el cáncer de páncreas como caso de estudio

15/10/2014

Biomateriales y biotecnología: desde el descubrimiento de los inhibidores angiogénicos hasta el desarrollo de los sistemas de liberación controlada de fármacos y la ingeniería de tejido

15/10/2014